-
1.发明公开
公开(公告)号：EP4284520A1
公开(公告)日：2023-12-06
申请号：EP22746474.0
申请日：2022-01-25
发明人： SHEPPARD, Dean , BIDLINGMAIER, Scott , LIU, Bin , ATAKILIT, Amha
-
公开(公告)号：EP3765005A1
公开(公告)日：2021-01-20
申请号：EP19766565.6
申请日：2019-03-13
IPC分类号： A61K31/17 , C07C275/16 , C07C275/24
-
3.发明授权
-
公开(公告)号：EP3847194A1
公开(公告)日：2021-07-14
申请号：EP19772925.4
申请日：2019-09-05
-
公开(公告)号：EP3436046A2
公开(公告)日：2019-02-06
申请号：EP17776794.4
申请日：2017-03-31
IPC分类号： A61K38/05 , C07D403/12 , C07D413/12
-
6.发明公开METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN 审中-公开方法和组合物与AVB8整联蛋白有关的疾病的治疗和预防
公开(公告)号：EP2981554A2
公开(公告)日：2016-02-10
申请号：EP14778764.2
申请日：2014-04-01
IPC分类号： C07K16/28
摘要： Antibodies (e.g., isolated antibodies) that specifically bind to human integrin β8 and inhibit adhesion of latency associated peptide (LAP) to αvβ8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin β8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to αβ8 with an IC50 below 5 nM.
-
7.发明公开METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH ALPHA V BETA 5 INTEGRIN 有权方法和组合物用于治疗和预防用αV BETA 5整联蛋白相关疾病的
公开(公告)号：EP1734996A2
公开(公告)日：2006-12-27
申请号：EP05763460.2
申请日：2005-03-30
发明人： SHEPPARD, Dean , ATAKILIT, Amha
IPC分类号： A61K39/395 , G01N33/53 , C12N5/20 , C07K16/28
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/70
摘要： The present invention provides compositions and methods for treating and preventing disease associated with αvß5 integrin by blocking binding to αVβ5 integrin.
-
8.发明公开
公开(公告)号：EP3747907A3
公开(公告)日：2021-02-24
申请号：EP20179661.2
申请日：2014-04-01
摘要： Methods and compositions comprising integrin β8 antibodies are provided.
-
9.发明授权METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH ALPHA V BETA 5 INTEGRIN 有权治疗和预防与αVβ5整联蛋白相关的疾病的方法和组合物
公开(公告)号：EP2394662B1
公开(公告)日：2018-03-21
申请号：EP11180077.7
申请日：2005-03-30
发明人： SHEPPARD, Dean , ATAKILIT, Amha
IPC分类号： A61K39/395 , G01N33/53 , C12N5/20 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/70
摘要： The invention provides an antibody that specifically binds to ±v²5 integrin with a K D of 0.01 µM or better. The antibody is useful for treating or preventing diseases such as pulmonary edema.
-
公开(公告)号：EP1490110B1
公开(公告)日：2012-06-13
申请号：EP03755325.2
申请日：2003-03-13
发明人： VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号： C07K16/28 , A61K39/395 , A61K47/48 , A61P17/06 , A61P35/00 , A61P13/12 , A61P11/00 , A61P1/16 , G01N33/577 , C12N15/13 , C12N5/20
CPC分类号： C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要： A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.
摘要翻译： （a）特异性结合±v26但不结合其他av整合素的单克隆抗体或其抗原结合片段; 和（b）不抑制结合26与潜伏相关肽（LAP）的结合，IC 50值低于10D5。 所述单克隆抗体，其中所述抗体包含a）与由杂交瘤6 2A1（ATCC登录号PTA-3896）产生的抗体相同的重链和轻链多肽序列或b）与所产生的抗体相同的重链和轻链多肽序列 通过杂交瘤6.2E5（ATCC登录号PTA-3897）。 本公开还涉及其用途和包含其的组合物。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.013 秒)
